BHVN Stock Summary and Trading Ideas (Biohaven Ltd. Common Shares | NYSE:BHVN)

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Biohaven Ltd. Common Shares trades on the NYSE stock market under the symbol BHVN.

As of February 4, 2026, BHVN stock price declined to $10.99 with 2,088,727 million shares trading.

BHVN has a beta of 1.66, meaning it tends to be more sensitive to market movements. BHVN has a correlation of 0.07 to the broad based SPY ETF.

BHVN has a market cap of $1.46 billion. This is considered a Small Cap stock.

Last quarter Biohaven Ltd. Common Shares reported $0 in Revenue and -$1.47 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.26.

In the last 3 years, BHVN traded as high as $62.21 and as low as $7.48.

The top ETF exchange traded funds that BHVN belongs to (by Net Assets): XBI, IWM, VXF, PINK, IBB.

BHVN has underperformed the market in the last year with a price return of -72.0% while the SPY ETF gained +15.2%. BHVN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.2% and -14.6%, respectively, while the SPY returned +1.9% and +0.1%, respectively.

BHVN support price is $10.64 and resistance is $12.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHVN shares will trade within this expected range on the day.